Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – , a provider of life sciences services to companies and drug developers worldwide, is forming its first drug development alliance in Asia.

The privately held company said Monday it has formed its first “Prime Site” in the Far East with the University Malaya Medical Centre.

Financial terms were not disclosed.

Quintiles already operates four Prime Sites in the U.S., Europe and Africa.

The goal of the alliances is to promote faster development of new and more effective drugs.

"Malaysia is an increasingly important player in Asia-Pacific clinical drug development and the commitment of its government, academic and private industry leaders to promoting leading-edge clinical research in the country is undeniable,” said Anand Tharmaratnam, head of Clinical Development for Quintiles Asia-Pacific.

“This, coupled with the highly skilled clinical workforce, strong clinical research infrastructure and large potential patient populations makes Malaysia and UMMC a quality fit as our first Prime Site in Asia," Tharmaratnam added. "With the enthusiasm and vision for this model that our UMMC partner has shown, we are confident that this will serve as a strong foundation for our Prime Site program in Asia."

Quintiles operates other Prime Sites at Queen Mary’s College in London, the Washington Hospital Center in Washington, D.C., The University of Pretoria, South Africa, and the Southern California Permanente Medical Group.

Get the latest news alerts: at Twitter.